Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S AbramsonMassachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address: [email protected]M. Lia PalombaMemorial Sloan Kettering Cancer Center, New York, NY, USALeo I. GordonNorthwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USAMatthew A. LunningUniversity of Nebraska Medical Center, Omaha, NE, USAMichael WangUniversity of Texas MD Anderson Cancer Center, Houston, TX, USAJon ArnasonBeth Israel Deaconess Medical Center, Boston, MA, USAAmitkumar MehtaUniversity of Alabama at Birmingham, Birmingham, AL, USAEnkhtsetseg PurevUniversity of Colorado School of Medicine, Aurora, CO, USADavid G. MaloneyFred Hutchinson Cancer Research Center, Seattle, WA, USACharalambos AndreadisUniversity of California, San Francisco, San Francisco, CA, USAAlison R. SehgalUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USAScott R. SolomonNorthside Hospital Cancer Institute, Atlanta, GA, USANilanjan GhoshLevine Cancer Institute, Atrium Health, Charlotte, NC, USATina AlbertsonJuno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USAJacob GarciaJuno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USAAna KostićJuno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USAMary MallaneyJuno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USAK. OGASAWARABristol-Myers Squibb, Princeton, NJ, USAKathryn J. NewhallBristol-Myers Squibb, Seattle, WA, USAYeonhee KimJuno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USAD. LiJuno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USATanya SiddiqiCity of Hope National Medical Center, Duarte, CA, USA
2020en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0